Clinical Trials Logo

Axial Spondyloarthritis clinical trials

View clinical trials related to Axial Spondyloarthritis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06310057 Completed - Clinical trials for Axial Spondyloarthritis

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to assess the efficacy of tofacitinib in refractory axial spodyloarthritis (ax-SpA) with dose escalation from 10mg to 15mg. Patients will start on 10mg and then divided into 2 groups (10 and 15) at 3rd month according to major improvement criteria. The main question[s] it aims to answer are: - Efficacy and safety of tofacitinib in different doses - If escalation of tofacitinib is justified if clinical criteria is not fulfilled at 10mg

NCT ID: NCT06230952 Completed - Clinical trials for Axial Spondyloarthritis

Reliability of BASDAI and BASFI Applied by Tele-Assessment Method in Axial SpA Spondyloarthritis

Start date: February 8, 2024
Phase:
Study type: Observational

The goal of this observational study is to investigate the reliability of BASDAI and BASFI questionnaires applied via tele-assessment in axial spondyloarthritis patients.

NCT ID: NCT05942976 Completed - Clinical trials for Rheumatoid Arthritis

Enthesis Differences in Rheumatoid Arthritis and Axial Spondyloarthropathy

Start date: June 16, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to investigate the sonographic differences in entheses in patients with Rheumatoid arthritis and Axial Spondyloarthropathy.

NCT ID: NCT05914532 Completed - Clinical trials for Axial Spondyloarthritis

New Biomarkers in Axial Sypondyloarthropathy; SII and SIRI

Start date: June 22, 2023
Phase:
Study type: Observational

investigators aimed to evaluate the relationship between Systemic Immune Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and disease activity in patients with axial spondyloarthropathy (SpA).

NCT ID: NCT05771389 Completed - Psoriatic Arthritis Clinical Trials

RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis

Start date: March 21, 2023
Phase: N/A
Study type: Interventional

Unlike other rheumatic diseases, acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with Spondyloarthropathies (SpA). Also, it is not possible to monitor disease activity with these tests. On the other hand, HLA-B27 positivity varies between races, and 8% of the normal population is HLA-B27 positive. In this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. Acute phase reactants are not sensitive for diagnosing and assessing disease activity. This may lead to a diagnostic delay of up to 9 years. The investigators hypothesize that Raftlin-1, thought to have a regulatory role in TH17 function and IL-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.

NCT ID: NCT05677542 Completed - Psoriatic Arthritis Clinical Trials

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Start date: June 2, 2021
Phase:
Study type: Observational

This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.

NCT ID: NCT05327140 Completed - Clinical trials for Axial Spondyloarthritis

Reliability of IBP Criteria & Activity Scores in Patients With AxSpA

IBP/AxSpA
Start date: August 20, 2021
Phase:
Study type: Observational

The current ASAS classification of AxSpA relies either on sacroiliitis on imaging plus one SpA feature (imaging arm) or HLA-B27 antigen plus two SpA features (clinical arm), in a patient with chronic back pain and age at onset of less than 45 years. IBP which is a major symptom of SpA depends more on patient's perception which is not usually accurate. As well, disease activity is measured by ASDAS, BASDAI, and BASFAI which depend more on subjective measures. Assessment of reliability of IBP criteria, ASDAS, BASDAI, and BASFAI in diagnosis and evaluation of activity of AxSpA is essential for better health care.

NCT ID: NCT05162937 Completed - Clinical trials for Axial Spondyloarthritis

to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

Start date: September 7, 2020
Phase: Phase 2
Study type: Interventional

Dosage: 100mg or 200mg or 300mg Administration frequency: Q2W administration in the first 4 weeks (W0, W2, W4), and subsequent Q4W administration (W8, W12) Administration: subcutaneous injection Specifications: 100mg/ 1mL/bottle or placebo 0mg/1ml/ bottle

NCT ID: NCT05031767 Completed - Clinical trials for Axial Spondyloarthritis

Remote Monitoring of Axial Spondyloarthritis

ReMonit
Start date: September 7, 2021
Phase: N/A
Study type: Interventional

The ReMonit study is a 18-months, non-inferiority randomized, controlled trial with three parallel arms to determine if two, new follow-up strategies for patients with axial spondyloarthritis (axSpA) are non-inferior in maintaining stable, low disease activity over time compared to the conventional follow-up regimen with regular hospital visits.

NCT ID: NCT05021783 Completed - Inflammation Clinical Trials

The Relationship Between Magnetic Resonance Imaging (MRI) Scores and Sensory Testing in Axial Spondyloarthritis

Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Axial spondyloarthritis is one of the most common rheumatic diseases and chronic pain and morning stiffness are the main complaints of these patients. Central sensitization is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies. There is no method for the diagnosis of central sensitization is accepted as a gold standard. The clinical scales and quantitative sensory testing (QST) widely is used for this purpose widely. The most commonly used QST types include pressure pain threshold (PPT), temporal summation (TS) and conditioned pain modulation (CPM). The well-known scale used for the evaluation of central sensitization is the Central Sensitization Inventory (CSI) , developed in 2011 for detect central sensitization in chronic pain patients. In this study, it was aimed to investigate the relationship between QST and CSI and sacroiliac MRI changes.